National Institute for Health and Care Excellence6m
Should NICE’s cost-effectiveness thresholds change?
Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...
National Institute for Health and Care Excellence3d
New price deal paves way for NICE approval of treatment for rare genetic condition
New analysis presented by the company, together with an improved discount to the price of vamorolone, mean that NICE can now ...
National Institute for Health and Care Excellence7d
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487
Suggested remit: To appraise the clinical and cost effectiveness of glycopyrronium bromide cream within its marketing authorisation for treating severe primary axillary hyperhidrosis.
National Institute for Health and Care Excellence7d
In consultation: Guidance and quality standards
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...
National Institute for Health and Care Excellence3d
NICE newsletters and alerts
Bringing you our latest news, features and guidance. Subscribe for information on: our latest guidance implementation advice and case studies consultations, meetings and events the latest news, ...
National Institute for Health and Care Excellence6d
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence6d
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484
A list of downloadable documents created during development.